Monalizumab

Drug Profile

Monalizumab

Alternative Names: Anti-NKG2A; IPH-2201; NN-8765; NNC 0141-0000-0100

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Innate Pharma; Novo Nordisk
  • Developer Innate Pharma; MedImmune; NCIC Clinical Trials Group; Novo Nordisk
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action NK cell lectin-like receptor subfamily C antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Haematological malignancies; Solid tumours
  • Discontinued Inflammation; Rheumatoid arthritis

Most Recent Events

  • 01 Apr 2017 Adverse events data from a phase I/II trial in Head and neck cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Jan 2017 Innate Pharma terminates a phase II trial in Head and neck cancer (Late-stage disease, Metastatic disease, First-line therapy, Neoadjuvant therapy) in Spain and Germany due to lack of recruitment (IV) (NCT02331875)
  • 30 Nov 2016 Preliminary safety and efficacy data from a phase I/II trial in Ovarian cancer and Fallopian tube carcinoma released by Innate Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top